Deutsche Bank’s Sage Therapeutics SAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-215,905
Closed -$1.97M 3710
2025
Q2
$1.97M Sell
215,905
-8,077
-4% -$59.4K ﹤0.01% 1716
2025
Q1
$1.78M Buy
223,982
+173,164
+341% +$1.27M ﹤0.01% 1832
2024
Q4
$276K Buy
50,818
+20,504
+68% +$125K ﹤0.01% 2954
2024
Q3
$219K Buy
30,314
+3,411
+13% +$31.2K ﹤0.01% 2886
2024
Q2
$292K Sell
26,903
-1,003,592
-97% -$12.9M ﹤0.01% 2612
2024
Q1
$19.3M Buy
1,030,495
+2,740
+0.3% +$63.2K 0.01% 827
2023
Q4
$22.3M Sell
1,027,755
-546
-0.1% -$10.8K 0.01% 769
2023
Q3
$21.2M Sell
1,028,301
-6,440
-0.6% -$186K 0.01% 687
2023
Q2
$48.7M Buy
1,034,741
+257,328
+33% +$12.8M 0.03% 518
2023
Q1
$32.6M Buy
777,413
+249,494
+47% +$10.7M 0.02% 638
2022
Q4
$20.1M Sell
527,919
-30,949
-6% -$1.18M 0.01% 759
2022
Q3
$21.9M Sell
558,868
-9,089
-2% -$351K 0.01% 736
2022
Q2
$18.3M Sell
567,957
-11,385
-2% -$382K 0.01% 801
2022
Q1
$19.2M Sell
579,342
-27,800
-5% -$1.05M 0.01% 848
2021
Q4
$25.8M Sell
607,142
-24,945
-4% -$1.04M 0.01% 778
2021
Q3
$28M Buy
632,087
+25,177
+4% +$1.15M 0.01% 777
2021
Q2
$34.5M Sell
606,910
-35,627
-6% -$2.52M 0.02% 729
2021
Q1
$48.1M Sell
642,537
-73,528
-10% -$6.03M 0.03% 602
2020
Q4
$61.9M Buy
716,065
+441,228
+161% +$32.5M 0.04% 433
2020
Q3
$16.8M Sell
274,837
-41,858
-13% -$2.12M 0.01% 765
2020
Q2
$13.2M Sell
316,695
-122,863
-28% -$4.46M 0.01% 855
2020
Q1
$12.6M Buy
439,558
+79,314
+22% +$4.59M 0.01% 837
2019
Q4
$26M Buy
360,244
+235,590
+189% +$29M 0.02% 689
2019
Q3
$17.5M Sell
124,654
-21,826
-15% -$3.65M 0.01% 834
2019
Q2
$26.8M Buy
146,480
+67,147
+85% +$11.5M 0.02% 823
2019
Q1
$12.6M Sell
79,333
-57,587
-42% -$8.34M 0.01% 1255
2018
Q4
$13.1M Sell
136,920
-35,756
-21% -$4.09M 0.01% 1135
2018
Q3
$24.4M Sell
172,676
-4,584
-3% -$708K 0.01% 1020
2018
Q2
$27.7M Sell
177,260
-126,635
-42% -$19.9M 0.01% 984
2018
Q1
$48.9M Buy
303,895
+152,116
+100% +$25.8M 0.02% 659
2017
Q4
$25M Sell
151,779
-226,840
-60% -$22M 0.02% 873
2017
Q3
$23.6M Sell
378,619
-281,794
-43% -$22.1M 0.02% 927
2017
Q2
$52.6M Sell
660,413
-13,458
-2% -$973K 0.04% 500
2017
Q1
$47.9M Sell
673,871
-229,764
-25% -$13.5M 0.04% 525
2016
Q4
$46.1M Sell
903,635
-128,791
-12% -$6.07M 0.04% 518
2016
Q3
$47.5M Buy
1,032,426
+615,414
+148% +$25M 0.03% 541
2016
Q2
$12.6M Buy
417,012
+122,441
+42% +$4.08M 0.01% 1169
2016
Q1
$9.44M Buy
294,571
+255,293
+650% +$8.99M 0.01% 1295
2015
Q4
$2.29M Buy
39,278
+21,280
+118% +$1.05M ﹤0.01% 2341
2015
Q3
$760K Sell
17,998
-2,680
-13% -$165K ﹤0.01% 3111
2015
Q2
$1.51M Sell
20,678
-1,395
-6% -$89.7K ﹤0.01% 2689
2015
Q1
$1.11M Buy
22,073
+9,395
+74% +$404K ﹤0.01% 2827
2014
Q4
$463K Sell
12,678
-5,123
-29% -$191K ﹤0.01% 3730
2014
Q3
$560K Buy
+17,801
New +$516K ﹤0.01% 3417

Other funds holding SAGE

Deutsche Bank's SAGE Position: Q3 2025 in Review

Deutsche Bank sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 215,905 shares — an estimated $1.97M sold.

Deutsche Bank first reported a position in SAGE in Q3 2014 and held it in 44 quarters. The position peaked at $61.9M in Q4 2020. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Deutsche Bank reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Deutsche Bank sold 215,905 Sage Therapeutics shares in Q3 2025, an estimated $1.97M.
  • Deutsche Bank first reported a position in Sage Therapeutics in Q3 2014 and held it in 44 quarters.
  • Deutsche Bank's Sage Therapeutics position peaked at $61.9M in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Deutsche Bank's 13F filing for Q3 2025, filed 13 Nov 2025.